Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection

References

• Feingold KR, Krauss RM, Pang M, et al. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab. 1993;76:1423–1427.
   PubMed Web of Science ®Google Scholar
• Shor-Posner G, Basit A, Lu Y, et al. Hypercholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med. 1993;94:515–519.
   PubMed Web of Science ®Google Scholar
• Buchacz K, Baker RK, Palella FJ Jr, et al. HIV outpatient study investigators. Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US. Antivir Ther. 2013;18(1):65–75.
   PubMed Web of Science ®Google Scholar
• Tóth PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the United States: the national health and nutrition examination survey 2003–2006. J Clin Lipidol. 2012;6(4):325–330.
   PubMed Web of Science ®Google Scholar
• Gili S, Grosso Marra W, D’Ascenzo F, et al. Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. Eur Heart J. 2016;37(48):3600–3609.
   PubMed Web of Science ®Google Scholar
• Khovidhunkit W, Memon RA, Feingold KR, et al. Infection and Inflammation-Induced Proatherogenic Changes of Lipoproteins. J Infect Dis. 2000;181(Suppl 3):S462–72.
   PubMed Web of Science ®Google Scholar
• Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978–2982.
   PubMed Web of Science ®Google Scholar
• Mujawar Z, Rose H, Morrow MP, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol. 2006;4(11):e365.
   PubMed Web of Science ®Google Scholar
• Sekhar RV, Jahoor F, White AC, et al. Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab. 2002;283:E332–E337.
   PubMed Web of Science ®Google Scholar
• Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045–1052.
   PubMed Web of Science ®Google Scholar
• Reeds DN, Mittendorfer B, Patterson BW, et al. Alterations in lipid kinetics in men with HIV-dyslipidemia. Am J Physiol Endocrinol Metab. 2003;285:E490–E497.
   PubMed Web of Science ®Google Scholar
• Dron JS, Hegele RA. Polygenic influences on dyslipidemias. Curr Opin Lipidol. 2018;29:133–143.
   PubMed Web of Science ®Google Scholar
• Egaña-Gorroño L, Martínez E, Cormand B, et al. Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy. AIDS. 2013;27:529–538.
   PubMed Web of Science ®Google Scholar
• Enkhmaa B, Anuurad E, Zhang W, et al. HIV disease activity as a modulator of lipoprotein(a) and allele-specific apolipoprotein(a) levels. Arterioscler Thromb Vasc Biol. 2013;33:387–392.
   PubMed Web of Science ®Google Scholar
• MacInnes A, Lazzarin A, Di Perri G, et al. Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: results from the MERIT trial. HIV Clin Trials. 2011;12(1):24–36.
   PubMed Web of Science ®Google Scholar
• Fung HB, Guo Y. Enfuvirtide: a fusion inhibitor for the treatment of HIV infection. Clin Ther. 2004;26(3):352–378.
   PubMed Web of Science ®Google Scholar
• Quercia R, Roberts J, Martin-Carpenter L, et al. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin Drug Investig. 2015;35(3):211–219.
   PubMed Web of Science ®Google Scholar
• Anastos K, Lu D, Shi Q, et al. Association of serum lipid levels with HIV serostatus. Specific antiretroviral agents, and treatment Regimens. J Acquir Immune Defic Syndr. 2007;45:34–42.
   PubMed Web of Science ®Google Scholar
• Ofotokun I, Na LH, Landovitz RJ, et al. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015;60(12):1842–1851.
   PubMed Web of Science ®Google Scholar
• Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomized, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390(10107):2073–2082. (Supplemental Appendix).
   PubMed Web of Science ®Google Scholar
• Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomized, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606–2615.
   PubMed Web of Science ®Google Scholar
• Tebas P, Sension M, Arribas J, et al. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials. Clin Infect Dis. 2014;59(3):425–434.
   PubMed Web of Science ®Google Scholar
• Orkin C, Squires KE, Molina JM, et al. Doravirine/Lamivudine/Tenofovir disoproxil fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial. Clin Infect Dis. 2019;68(4):535–544.
   PubMed Web of Science ®Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372(9639):646–655.
   PubMed Web of Science ®Google Scholar
• Tungsiripat M, Kitch D, Glesby MJ, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010;24:1781–1784.
   PubMed Web of Science ®Google Scholar
• Wohl D, Arnoczy G, Fichtenbaum CJ, et al. Cardiovascular disease (CVD) risk markers in patients receiving abacavir, tenofovir, and zidovudine: the nucleoside inflammation, coagulation and endothelial function (NICE) study. Antivir Ther. 2014;19(2):141–147.
   PubMed Web of Science ®Google Scholar
• Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomized double-blind active-controlled trial. Lancet. 2011;378:238–246.
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomized, non-inferiority trial. Lancet. 2011;378:229–237.
   PubMed Web of Science ®Google Scholar
• Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation. 1999;100:700–705.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services. [cited 2019 Jun 25]. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
   Google Scholar
• Landovitz RJ, Zangeneh SZ, Chau G, et al. Cabotegravir is not associated with weight gain in HIV-negative individuals: HPTN 077. Conference on Retroviruses and Opportunistic Infections (CROI); 2019 Mar 4–7; Seattle, WA. Abstract 34.
   Google Scholar
• Bourgi K, Jenkins C, Rebeiro PF, et al. Greater weight gain among treatment-naïve persons starting integrase inhibitors. Conference on Retroviruses and Opportunistic Infections (CROI); 2019 Mar 4–7; Seattle, WA. Abstract 670.
   Google Scholar
• Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506–2512.
   PubMed Web of Science ®Google Scholar
• Freiberg MS, Chang CH, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8):614–622.
   PubMed Web of Science ®Google Scholar
• Anoop SV, Shah ASV, Stelzle D, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV. Circulation. 2018;138:1100–1112.
   PubMed Web of Science ®Google Scholar
• Lo J, Abbara S, Shturman L, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS. 2010;24:243–253.
   PubMed Web of Science ®Google Scholar
• Post WS, Budoff M, Kingsley L, et al. Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med. 2014;160(7):458–467.
   PubMed Web of Science ®Google Scholar
• Martin-Iguacel R, Llibre JM, Friis-Moller N. Risk of cardiovascular disease in an aging HIV population: where are we now? Curr HIV/AIDS Rep. 2015;12(4):375–387.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation. 2018 Nov 10:CIR0000000000000625. [Epub ahead of print]. DOI: 10.1161/CIR.0000000000000625.
   Web of Science ®Google Scholar
• Feinstein MJ, Nance RM, Drozd DR, et al. Assessing and refining myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the centers for AIDS research network of integrated clinical systems. JAMA Cardiol. 2017;2(2):155–162.
   PubMed Web of Science ®Google Scholar
• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532–2561.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017;376(16):1527–1539.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet. 2010;376(9753):1670–1681.
   PubMed Web of Science ®Google Scholar
• Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120(1):229–243.
   PubMed Web of Science ®Google Scholar
• Aberg JA, Zackin RA, Brobst SW, et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS clinical trials group study 5087. AIDS Res Hum Retroviruses. 2005;21(9):757–767.
   PubMed Web of Science ®Google Scholar
• Singh S, Willig JH, Mugavero MJ, et al. Comparative effectiveness and toxicity of statins among HIV-infected patients. Clin Infect Dis. 2011;52(3):387–395.
   PubMed Web of Science ®Google Scholar
• Eckard AR, Jiang Y, Debanne SM, et al. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis. 2014;209(8):1156–1164.
   PubMed Web of Science ®Google Scholar
• Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Aquir Immune Defic Syndr. 2015;68:396–404.
   PubMed Web of Science ®Google Scholar
• Aberg JA, Sponseller CA, Ward DJ, et al. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomized, double-blind, superiority trial. Lancet HIV. 2017;4(7):e284–e294.
   PubMed Web of Science ®Google Scholar
• Calza L, Colangeli V, Manfredi R, et al. Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS. 2005;19:1103–1108.
   PubMed Web of Science ®Google Scholar
• Calza L, Manfredi R, Colangeli V, et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS. 2005;19(10):1051–1058.
   PubMed Web of Science ®Google Scholar
• Palacios R, Santos J, González M, et al. Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;30(5):536–537.
   PubMed Web of Science ®Google Scholar
• Nixon DE, Bosch RJ, Chan ES, et al. Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL. J Clin Lipidol. 2017;11(1):61–69.
   PubMed Web of Science ®Google Scholar
• Lo J, Lu MT, Ihenachor EJ, et al. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomized, double-blind, placebo-controlled trial. Lancet HIV. 2015;2(2):e52–e63.
   PubMed Web of Science ®Google Scholar
• Longenecker CT, Sattar A, Gilkeson R, et al. Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection. AIDS. 2016;30(14):2195–2203.
   PubMed Web of Science ®Google Scholar
• Hileman CO, Turner R, Funderburg NT, et al. Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV. AIDS. 2016;30(1):65–73.
   PubMed Web of Science ®Google Scholar
• Nou E, Lu MT, Looby SE, et al. Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV. AIDS. 2016;30(4):583–590.
   PubMed Web of Science ®Google Scholar
• Longenecker CT, Eckard AR, McComsey GA. Statins to improve cardiovascular outcomes in treated HIV infection. Curr Opin Infect Dis. 2016;29(1):1–9.
   PubMed Web of Science ®Google Scholar
• Toribio M, Fitch KV, Sanchez L, et al. Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV. AIDS. 2017;31(6):797–806.
   PubMed Web of Science ®Google Scholar
• Calza L, Colangeli V, Magistrelli E, et al. Significant decrease in plasma levels of D-Dimer, Interleukin-8, and Interleukin-12 after a 12-month treatment with rosuvastatin in HIV-infected patients under antiretroviral therapy. AIDS Res Hum Retroviruses. 2017;33(2):126–132.
   PubMed Web of Science ®Google Scholar
• Grinspoon SK, Fitch KV, Overton ET, et al. Rationale and design of the randomized trial to prevent cardiovascular events in HIV (REPRIEVE). Am Heart J. 2019;212:23–35.
   PubMed Web of Science ®Google Scholar
• Hoffmann U, Lu MT, Olalere D, et al. Rationale and design of the mechanistic substudy of REPRIEVE: effects of pitavastatin on coronary artery disease and inflammatory biomarkers. Am Heart J. 2019;212:1–12.
   PubMed Web of Science ®Google Scholar
• Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet. 1998;35(4):275–291.
   PubMed Web of Science ®Google Scholar
• Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in HIV-infected adults receiving antiretroviral therapy. Updated recommendations of the Adult AIDS Clinical Trials Group Cardiovascular Subcommittee. Clin Infect Dis. 2003;37:613–627.
   PubMed Web of Science ®Google Scholar
• Calza L, Manfredi R, Colangeli V, et al. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk. AIDS Res Hum Retroviruses. 2013;29(3):547–556.
   PubMed Web of Science ®Google Scholar
• Stein JH, Merwood MA, Bellehumeur JL, et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J. 2004;147(4):E18.
   PubMed Web of Science ®Google Scholar
• Hürlimann D, Chenevard R, Ruschitzka F, et al. Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing anti-retroviral combination therapy: a randomized double blind crossover trial. Heart. 2006;92(1):110–112.
   PubMed Web of Science ®Google Scholar
• Ganesan A, Crum-Cianflone N, Higgins J, et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis. 2011;203(6):756–764.
   PubMed Web of Science ®Google Scholar
• Shah BM, Schafer JJ, Priano J, et al. Cobicistat: a new boost for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2013;33(10):1107–1116.
   PubMed Web of Science ®Google Scholar
• Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG study A5047. AIDS. 2002;16(4):569–577.
   PubMed Web of Science ®Google Scholar
• Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS clinical trials group 5108 study. J Acquir Immune Defic Syndr. 2005;39(3):307–312.
   PubMed Web of Science ®Google Scholar
• Sameneni DY, Sallans L, Desai PB, et al. Steady state pharmacokinetic interactions of Darunavir/ritonavir with lipid lowering agent rosuvastatin. J Clin Pharmacol. 2012;52(6):922–931.
   PubMed Web of Science ®Google Scholar
• Kiser JJ, Gerber JG, Predhomme JA, et al. Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr. 2008;47(5):570–578.
   PubMed Web of Science ®Google Scholar
• Elsby R, Martin P, Surry D, et al. Solitary inhibition of the breast cancer resistance protein efflux transporter results in a clinically significant drug-drug interaction with rosuvastatin by causing up to a 2-fold increase in statin exposure. Drug Metab Dispos. 2016;44:398–408.
   PubMed Web of Science ®Google Scholar
• Fujimoto H, Higuchi M, Watanabe H, et al. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. Biol Pharm Bull. 2009;32(9):1588–1593.
   PubMed Web of Science ®Google Scholar
• Wiggins BS, Lamprecht DG Jr, Page RL 2nd, et al. Recommendations for managing drug-drug interactions with statins and HIV medications. Am J Cardiovasc Drugs. 2017 Oct;17(5):375–389.
   PubMed Web of Science ®Google Scholar
• Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114(25):2788–2797.
   PubMed Web of Science ®Google Scholar
• Chou R, Dana T, Blazina I, et al. Statins for prevention of cardiovascular disease in adults evidence report and systematic review for the US preventive services task force. JAMA. 2016;316(19):2008–2024.
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet. 2010;375:735–742.
   PubMed Web of Science ®Google Scholar
• GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999;354:447–455.
   PubMed Web of Science ®Google Scholar
• Simons LA, Hickie JB, Balasubramaniam S. On the effects of dietary n-3 fatty acids (Maxepa) on plasma lipids and lipoproteins in patients with hyperlipidaemia. Atherosclerosis. 1985;54:75–88.
   PubMed Web of Science ®Google Scholar
• The REDUCE-IT trial analyzed the effects of high dose icosapent ethyl on HIV negative patients (Bhatt). The study focused on patients who had elevated TG levels despite receiving statin treatment. The study indicated that patients receiving two doses of 2 g icosapent ethyl daily had significantly lower TG levels than the placebo.
   Google Scholar
• Muñoz MA, Liu W, Delaney JAC, et al. Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care. J Acquir Immune Defic Syndr. 2013;64:254–260.
   PubMed Web of Science ®Google Scholar
• Wohl DA, Tien HC, Busby M, et al. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis. 2005 15;41(10):1498–1504.
   PubMed Web of Science ®Google Scholar
• De Truchis P, Kirstetter M, Perier A, et al. Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study. J Acquir Immune Defic Syndr. 2007;44(3):278–285.
   PubMed Web of Science ®Google Scholar
• Gerber JG, Kitch DW, Fichtenbaum CJ, et al. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186 protocol. J Acquir Immune Defic Syndr. 2008;47:459–466.
   PubMed Web of Science ®Google Scholar
• Sameneni D, Fichtenbaum CJ. Fenofibrate in the treatment of dyslipidemia associated with HIV infection. Expert Opin Drug Metab Toxicol. 2010;6:995–1004.
   PubMed Web of Science ®Google Scholar
• Miller J, Brown D, Amin J, et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridemia. AIDS. 2002;16(16):2195–2200.
   PubMed Web of Science ®Google Scholar
• Fruchart J-C. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol. 2017;16(1). DOI:10.1186/s12933-017-0602-y
   PubMed Web of Science ®Google Scholar
• Arai H, Yamashita S, Yokote K, et al. Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: a multicenter, placebo-controlled, double-blind, randomized trial. J Atheroscler Thromb. 2018;25(6):521–538.
   PubMed Web of Science ®Google Scholar
• Schandelmaier S, Briel M, Saccilotto R, et al. Niacin for primary and secondary prevention of cardiovascular events. Cochrane Database Syst Rev. 2017;6:CD009744. Review. .
   PubMedGoogle Scholar
• Dubé MP, Wu JW, Aberg JA, et al. Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS clinical trials group study A5148. Antivir Ther. 2006;11(8):1081–1089.
   PubMed Web of Science ®Google Scholar
• Balasubramanyam A, Coraza I, Smith EO, et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of “heart positive,” a randomized, controlled trial. J Clin Endocrinol Metab. 2011;96(7):2236–2247.
   PubMed Web of Science ®Google Scholar
• Dubé MP, Komarow L, Fichtenbaum CJ, et al. Extended-release niacin versus fenofibrate in HIV-infected participants with low high-density lipoprotein cholesterol: effects on endothelial function, lipoproteins, and inflammation. Clin Infect Dis. 2015;61(5):840–849.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397.
   PubMed Web of Science ®Google Scholar
• Wohl DA, Waters D, Simpson RJ Jr, et al. Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clin Infect Dis. 2008;47(8):1105–1108.
   PubMed Web of Science ®Google Scholar
• Chow D, Chen H, Glesby MJ, et al. Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients. AIDS. 2009;23(16):2133–2141.
   PubMed Web of Science ®Google Scholar
• Grandi AM, Nicolini E, Rizzi L, et al. Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy. J Int AIDS Soc. 2014;17:19004. eCollection 2014. .
   PubMed Web of Science ®Google Scholar
• Saeedi R, Johns K, Frohlich J, et al. Lipid lowering efficacy and safety of ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients. Lipids Health Dis. 2015;14:57.
   PubMed Web of Science ®Google Scholar
• Della Badia LA, Elshourbagy NA, Mousa SA. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol. Pharmacol Ther. 2016;164:183–194.
   PubMed Web of Science ®Google Scholar
• O’Keefe JH, DiNicolantonio JJ, Lavie CJ. Statins, ezetimibe, and proprotein convertase subtilisin-kexin type 9 inhibitors to reduce low-density lipoprotein cholesterol and cardiovascular events. Am J Cardiol. 2017;119(4):565–571.
   PubMed Web of Science ®Google Scholar
• Ference BA, Cannon CP, Landmesser U, et al. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the cholesterol treatment trialists collaboration. Eur Heart J. 2018;39(27):2540–2545.
   PubMed Web of Science ®Google Scholar
• Kohli M, Patel K, MacMahon Z, et al. Pro- protein subtilisin kexin- 9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres. Int J Clin Pract. 2017 Nov;71(11):e13032.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT02833844, safety, tolerability & efficacy on LDL-C of evolocumab in subjects with HIV & hyperlipidemia/mixed dyslipidemia. 2016 Jul 14. [cited 2019 Jun 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT02833844?term=NCT02833844&rank=1
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT03207945, effect of PCSK9 inhibition on cardiovascular risk in treated HIV infection (EPIC-HIV Study) (EPIC-HIV). 2017 Jul 5. [cited 2019 Jun 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03207945?term=NCT03207945&rank=1
   Google Scholar